Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

PURPOSE: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzaniga, Marina Elena, Danesi, Romano, Girmenia, Corrado, Invernizzi, Pietro, Elvevi, Alessandra, Uguccioni, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586706/
https://www.ncbi.nlm.nih.gov/pubmed/31065872
http://dx.doi.org/10.1007/s10549-019-05261-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586706/
https://www.ncbi.nlm.nih.gov/pubmed/31065872
http://dx.doi.org/10.1007/s10549-019-05261-5

Ejemplares similares